Neuren Pharmaceuticals (ASX:NEU) has announced the development of NNZ-2591 as a potential treatment for hypoxic-ischemic encephalopathy, a severe brain injury occurring in newborns due to insufficient ...
Opthea (ASX:OPT) hat bekannt gegeben, dass ihre COAST Phase 3 klinische Studie zur feuchten altersbedingten Makuladegeneration ihren primären Endpunkt nicht erreicht hat. Die Studie, die die ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback